Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
Co-administration of zavegepant nasal spray with a single dose of an oral contraceptive resulted in no clinically meaningful changes (<12% increase) in EE-LNG exposure.
Authors
- Richard Bertz (ORCID: https://orcid.org/0009-0006-4593-1310)
- Julie L. Collins (ORCID: https://orcid.org/0000-0002-3775-2703)
- Kyle Matschke (ORCID: https://orcid.org/0009-0003-2043-851X)
- Jennifer Madonia (ORCID: https://orcid.org/0009-0000-8060-8478)
- Jing Liu (ORCID: https://orcid.org/0000-0002-6730-9198)
- Rajinder Bhardwaj (ORCID: https://orcid.org/0009-0005-2720-2192)
Institutions
- Pfizer (United States) (US)
- Biohaven Pharmaceuticals (United States) (US)
- Certara (United States) (US)
- Integra LifeSciences (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/head.14863
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Pfizer